Cerebral protection.
The term cerebral protection has been incorporated into medical terminology to imply amelioration of acute neurological damage caused by a relative lack of metabolic substrate for cells in the central nervous system. For example this may result from hypoxaemia, cardiac arrest, stroke, trauma, inflammation, or metabolic abnormalities.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001463:Barbiturates / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D001929:Brain Edema / Q000188:drug therapy; D002545:Brain Ischemia / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002560:Cerebrovascular Circulation; D003128:Coma / Q000628:therapy; D006259:Craniocerebral Trauma / Q000628:therapy; D004234:Diuretics, Osmotic / Q000627:therapeutic use; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology; D007427:Intracranial Pressure / Q000187:drug effects; D010672:Phenytoin / Q000627:therapeutic use; D012138:Respiratory Therapy
D000305:Adrenal Cortex Hormones; D001463:Barbiturates; D001786:Blood Glucose; D002121:Calcium Channel Blockers; D004234:Diuretics, Osmotic; D010672:Phenytoin